Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fe0@HMON@DNA-Exo** is a research-stage, biologically logic-gated nano-Trojan-horse platform developed for **triple-negative breast cancer**. It consists of elemental iron synthesized within glutathione-responsive degradable hollow mesoporous organosilica nanoparticles and cloaked with DNA-fragment-containing exosomes derived from SN38-treated 4T1 breast cancer cells. In the high-glutathione, mildly acidic tumor microenvironment, iron release promotes Fenton-reaction reactive oxygen species generation and selective ferroptotic tumor-cell death. The DNA-containing exosomal shell also stimulates cGAS-STING signaling in antigen-presenting cells, promoting innate antitumor immunity. The platform has been reported in preclinical murine TNBC models and is not the same asset as Gate2Brain's G2B-002.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fe0@HMON@DNA-Exo.